RxDoctor Payments Data

Evanthia Galanis, MD

Medical Oncology · Rochester, MNNPI 1326028234

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Boehringer Ingelheim International GmbH accounts for 80.5% of it on its own, with 3 other manufacturers making up the rest.

$22,684in general payments, 2019–2025

Across 10 payments — averaging $2268.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$18K
  • Merck$2K
  • Agios Pharmaceuticals, Inc.$2K
  • AstraZeneca$500
$72,239,556in research payments, 2019–2025

Across 727 payments — averaging $99,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Pharmaceuticals LLC$45.3M
  • Pfizer$20.6M
  • Genentech, Inc.$1.9M
  • AstraZeneca$1.9M
  • Novartis$1.1M
  • Janssen Research & Development, LLC$775K
  • plus $630K from 6 others

What the payments were for

  • Consulting fees$11,30050%
  • Speaking & faculty fees$1,9258%
  • Travel & lodging$9,30541%
  • Food & beverage$1531%

General payments by program year

20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$22,684 in reported general payments places this provider in the 75th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$1,355,782
Medicare patients
241
Services billed
46,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →